OmniComm Systems, Inc. Wins a Phase II, Multi-Center International Clinical Trial for a Major West Coast Biopharmaceutical Company

FT. LAUDERDALE, FL--(MARKET WIRE)--Jun 11, 2007 -- OmniComm Systems, Inc. (OTC BB:OMCM.OB - News), one of the fastest growing companies in the EDC market place, today announced that it has begun working with a multi-billion dollar West Coast global pharmaceutical company on a Phase II, multi-center study. OmniComm's subsidiary in Europe, OmniComm Europe GMBH located in Bonn, Germany will provide full ASP hosted support and services for the duration of the trial.